GoKawiil
Tech News
Revolution Medicines received FDA approval this week for a pancreatic cancer pill, a milestone that comes after the company fielded acquisition interest from larger pharmaceutical firms but chose to remain independent. The decision allowed it to bring the drug through regulatory approval on its own rather than as part of a larger acquirer's pipeline.
The FDA has cleared daraxonrasib, a new drug for pancreatic cancer, after a large clinical trial found patients on the treatment survived roughly twice as long as those receiving standard chemotherapy. The approval gives doctors a new option for a disease long known for poor treatment outcomes.
The FDA has approved Rasonque (daraxonrasib), a once-daily pill designed to block multiple mutated forms of the RAS protein that drive most pancreatic adenocarcinoma tumors. It is cleared for adults with metastatic disease who have already tried one systemic treatment or cannot tolerate combination chemotherapy, and the agency says it acted ahead of its original review timeline.
An investigative essay traces how the US supplement market ballooned from roughly 4,000 products worth $4 billion in 1994 to as many as 100,000 products generating nearly $73 billion annually today, all under the same regulatory framework. Under that 1994 law, manufacturers never had to prove to the FDA that their products contain what labels claim or that health claims are accurate before selling them, and the government itself bears the burden of proving a product is adulterated. FDA official Cara Welch admits the agency has no systematic way of tracking what supplements exist or what they contain.
A Farm Action report examines Taylor Farms, the little-known produce supplier linked by the FDA to a 2026 Cyclospora outbreak that has sickened thousands and killed at least two people. The outbreak was traced to shredded iceberg lettuce served at Taco Bell, but the report shows Taylor Farms' products appear widely across grocery stores, restaurants, schools, and hospitals, often under different brand names.
The FDA has granted approval to a wearable sensor capable of monitoring both blood glucose and ketone levels simultaneously, marking the first authorization of its kind. The device is designed to give users continuous, real-time readings without separate testing tools for each metric.
The FDA has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged 2 and up. It is the first wearable in the U.S. to continuously track ketone levels and the first worldwide to combine continuous ketone and glucose monitoring in one device. Sensors measure both substances every minute in fluid beneath the skin and send readings wirelessly to a paired smartphone.
The FDA has approved PrecivityAD2, a blood test that detects amyloid and tau biomarkers linked to Alzheimer's disease in symptomatic patients starting at age 40. In a validation study of 1,142 adults, the test correctly identified positive biomarkers 97.6% of the time, even among patients with conditions like kidney disease or diabetes that can otherwise skew results.
The FDA has cleared PrecivityAD2, a blood test built on technology from Washington University School of Medicine, to help identify amyloid plaques linked to Alzheimer's disease. Developed by WashU spinoff C2N Diagnostics, the test uses high-resolution mass spectrometry to quantify biomarkers with over 90% accuracy, offering a less invasive option than spinal taps or brain imaging.